JP2019505164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505164A5 JP2019505164A5 JP2018522671A JP2018522671A JP2019505164A5 JP 2019505164 A5 JP2019505164 A5 JP 2019505164A5 JP 2018522671 A JP2018522671 A JP 2018522671A JP 2018522671 A JP2018522671 A JP 2018522671A JP 2019505164 A5 JP2019505164 A5 JP 2019505164A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- host cell
- fucose
- culture
- fucose source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 16
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 15
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 15
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 238000012258 culturing Methods 0.000 claims 5
- 230000033581 fucosylation Effects 0.000 claims 4
- 239000002609 medium Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 101150003160 X gene Proteins 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- PNNNRSAQSRJVSB-KCDKBNATSA-N aldehydo-L-fucose Chemical group C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-KCDKBNATSA-N 0.000 claims 1
- PTVXQARCLQPGIR-SXUWKVJYSA-N beta-L-fucose 1-phosphate Chemical group C[C@@H]1O[C@H](OP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O PTVXQARCLQPGIR-SXUWKVJYSA-N 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249828P | 2015-11-02 | 2015-11-02 | |
| US62/249,828 | 2015-11-02 | ||
| US201662338280P | 2016-05-18 | 2016-05-18 | |
| US62/338,280 | 2016-05-18 | ||
| PCT/US2016/059922 WO2017079165A1 (en) | 2015-11-02 | 2016-11-01 | Methods of making fucosylated and afucosylated forms of a protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505164A JP2019505164A (ja) | 2019-02-28 |
| JP2019505164A5 true JP2019505164A5 (enExample) | 2019-12-12 |
| JP6983772B2 JP6983772B2 (ja) | 2021-12-17 |
Family
ID=57326491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522671A Active JP6983772B2 (ja) | 2015-11-02 | 2016-11-01 | タンパク質のフコシル化及び脱フコシル化形態の作製方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10975168B2 (enExample) |
| EP (2) | EP3371206B1 (enExample) |
| JP (1) | JP6983772B2 (enExample) |
| KR (2) | KR20250051156A (enExample) |
| CN (2) | CN108431026B (enExample) |
| AU (2) | AU2016350732A1 (enExample) |
| BR (1) | BR112018007356A2 (enExample) |
| CA (1) | CA2999047A1 (enExample) |
| ES (1) | ES2875274T3 (enExample) |
| IL (1) | IL258161B2 (enExample) |
| MX (1) | MX2018004831A (enExample) |
| PL (1) | PL3371206T3 (enExample) |
| SG (2) | SG10202103875WA (enExample) |
| WO (1) | WO2017079165A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018004831A (es) | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
| JP6674028B2 (ja) * | 2016-01-06 | 2020-04-01 | アウトルック セラピューティクス，インコーポレイティド | モノクローナル抗体組成物中のアフコシル化種の調節 |
| CN110945028B (zh) | 2017-07-10 | 2023-09-08 | 国际药物发展生物技术公司 | 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤 |
| SG11202009216YA (en) * | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
| MX2020013036A (es) | 2018-06-05 | 2021-02-26 | Amgen Inc | Modulacion de la fagocitosis celular dependiente de anticuerpos. |
| MY197429A (en) * | 2018-08-29 | 2023-06-16 | United Biopharma Inc | Afucosylated antibodies and manufacture thereof |
| US20220033511A1 (en) | 2018-09-11 | 2022-02-03 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| MX2021011330A (es) | 2019-03-20 | 2021-12-10 | Univ California | Anticuerpos de claudina-6 y conjugados de fármacos. |
| JP7682797B2 (ja) | 2019-03-20 | 2025-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６二重特異性抗体 |
| BR112021022202A2 (pt) | 2019-05-06 | 2021-12-28 | Amgen Inc | Modulação de funções efetoras de anticorpo |
| KR20220069982A (ko) * | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
| EP4041773A1 (en) * | 2019-10-11 | 2022-08-17 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
| IL298825A (en) * | 2020-07-02 | 2023-02-01 | Gigagen Inc | ANTI-CTLA-4 binding proteins and methods of using them |
| TW202317614A (zh) | 2021-06-07 | 2023-05-01 | 美商安進公司 | 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平 |
| US20250073323A1 (en) * | 2021-08-06 | 2025-03-06 | Anyadi, Llc | Process for producing personalized cancer immunotherapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| WO2000018938A1 (en) | 1998-09-29 | 2000-04-06 | Pioneer Hi-Bred International, Inc. | Mar/sar elements flanking rsyn7-driven construct |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
| ATE437233T1 (de) | 2001-01-26 | 2009-08-15 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
| ATE430580T1 (de) * | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| CN1938428A (zh) | 2003-11-12 | 2007-03-28 | 先灵公司 | 多基因表达的质粒系统 |
| KR20080032065A (ko) * | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
| AU2006270718B2 (en) * | 2005-07-22 | 2011-07-21 | Kyowa Kirin Co., Ltd. | Genetically modified antibody composition |
| JP5298021B2 (ja) * | 2006-10-12 | 2013-09-25 | ジェネンテック， インコーポレイテッド | リンホトキシン−αに対する抗体 |
| PL2438171T3 (pl) * | 2009-06-02 | 2015-04-30 | Regeneron Pharma | Komórki z niedoborem fukozylacji |
| WO2010141855A1 (en) * | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| AU2012226398B9 (en) * | 2011-03-06 | 2017-04-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| EP3036320B2 (en) * | 2013-08-19 | 2024-04-03 | Biogen MA Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
| US10752674B2 (en) * | 2014-11-15 | 2020-08-25 | Zumutor Biologics Inc. | DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof |
| JP6587696B2 (ja) * | 2015-05-13 | 2019-10-09 | ズムトール バイオロジクス、インコーポレイテッド | アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法 |
| MX2018004831A (es) | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
-
2016
- 2016-11-01 MX MX2018004831A patent/MX2018004831A/es unknown
- 2016-11-01 KR KR1020257011036A patent/KR20250051156A/ko active Pending
- 2016-11-01 BR BR112018007356A patent/BR112018007356A2/pt not_active Application Discontinuation
- 2016-11-01 SG SG10202103875WA patent/SG10202103875WA/en unknown
- 2016-11-01 PL PL16797693T patent/PL3371206T3/pl unknown
- 2016-11-01 SG SG11201802773RA patent/SG11201802773RA/en unknown
- 2016-11-01 WO PCT/US2016/059922 patent/WO2017079165A1/en not_active Ceased
- 2016-11-01 ES ES16797693T patent/ES2875274T3/es active Active
- 2016-11-01 CN CN201680077178.3A patent/CN108431026B/zh active Active
- 2016-11-01 EP EP16797693.5A patent/EP3371206B1/en active Active
- 2016-11-01 CN CN202310074105.0A patent/CN116731147A/zh active Pending
- 2016-11-01 CA CA2999047A patent/CA2999047A1/en active Pending
- 2016-11-01 KR KR1020187009379A patent/KR102793554B1/ko active Active
- 2016-11-01 JP JP2018522671A patent/JP6983772B2/ja active Active
- 2016-11-01 EP EP21162187.5A patent/EP3925970A1/en active Pending
- 2016-11-01 AU AU2016350732A patent/AU2016350732A1/en not_active Abandoned
-
2018
- 2018-03-15 IL IL258161A patent/IL258161B2/en unknown
- 2018-05-01 US US15/968,214 patent/US10975168B2/en active Active
-
2021
- 2021-01-13 US US17/148,456 patent/US11802165B2/en active Active
-
2022
- 2022-04-13 AU AU2022202460A patent/AU2022202460A1/en not_active Abandoned
-
2023
- 2023-09-25 US US18/474,014 patent/US12391769B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505164A5 (enExample) | ||
| JP2016104045A5 (enExample) | ||
| Dinnis et al. | Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? | |
| JP6029625B2 (ja) | 製造方法 | |
| JP2019523221A5 (enExample) | ||
| CN103597073A (zh) | 低岩藻糖细胞系及其应用 | |
| EA201900326A1 (ru) | Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами | |
| SA518391704B1 (ar) | C5 أجسام مضادة لـ وطرق لاستخدامها | |
| MY183415A (en) | Anti-c5 antibodies and methods of use | |
| JP2014110814A5 (enExample) | ||
| HRP20211882T1 (hr) | Protutijela protiv cd40 i njihova upotreba | |
| Nishimiya | Proteins improving recombinant antibody production in mammalian cells | |
| MX2018006627A (es) | Aumentar el rendimiento de particulas similares a virus en plantas. | |
| JP2016513478A5 (enExample) | ||
| JP2008086326A (ja) | ゲノム性要素を使用する遺伝子の操作および発現 | |
| WO2018035364A1 (en) | Product and methods useful for modulating and evaluating immune responses | |
| JP2016513457A5 (enExample) | ||
| EP4269438A3 (en) | Oncolytic virus and method | |
| CR20200507A (es) | Composiciones aav, métodos de fabricación y métodos de uso | |
| EA201790136A1 (ru) | Регулирование процессов в биореакторе | |
| Shin et al. | Efficient CRISPR/Cas9-mediated multiplex genome editing in CHO cells via high-level sgRNA-Cas9 complex | |
| JP7416745B2 (ja) | 改変細胞、調製方法、及び構築物 | |
| O’Callaghan et al. | Building a cell culture process with stable foundations: searching for certainty in an uncertain world | |
| Park et al. | Effects of palindrome structure on Dhfr amplification in Chinese hamster ovary cells | |
| WO2024200858A2 (en) | Cho cells with optimized ecm profile |